Please login to the form below

Not currently logged in
Email:
Password:

Invega Trinza

This page shows the latest Invega Trinza news and features for those working in and with pharma, biotech and healthcare.

J&J files three-monthly schizophrenia drug in Europe

J&J files three-monthly schizophrenia drug in Europe

The three-monthly version was approved by the FDA as Invega Trinza in May on the back of clinical data showing that the drug was effective, preventing significant return of schizophrenic ... Xeplion/Invega Sustenna is already a big earner for J&J, with

Latest news

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Recovery looks different for everyone and the long-term symptom control offered by Invega Trinza can help patients work toward their own

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics